Stephen B. Guntrip

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15

Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Kenneth Down, Augustin Amour, Angela M. Deakin et al. · Journal of Medicinal Chemistry · 2015 · 132 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Stuart Cockerill, Colin Stubberfield, Jeremy N. Stables et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 80 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Micheal D. Gaul, Yu Guo, Karen Affleck et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 59 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors

Paul Beswick, Sharon Bingham, C. Bountra et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 46 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10